A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC

Trial Profile

A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Abemaciclib (Primary) ; Gemcitabine (Primary) ; LY 3023414 (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Ramucirumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms KEYNOTE-238
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Sep 2017 Results (n=29, Data cut off: 1 Mar 2017) of cohort D (Abema [100, 150 mg, or 200 mg] was given orally on a continuous schedule every 12 hours (q12h) with LY at 100, 150, or 200 mg q12h) presented at the 42nd European Society for Medical Oncology Congress
    • 29 Aug 2017 According to an Eli Lilly media release, results from this trial will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
    • 20 Jan 2017 Planned number of patients changed from 180 to 150.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top